Jeffrey Leon Myers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeffrey Leon Myers has a total of 191 co-authors. Here are the top co-authors by number of shared publications:
- Ganesh Raghu
Division of Pulmonary, Critical Care and Sleep Medicine, Center for Interstitial Lung Diseases, Department of Medicine, University of Washington
7 shared publications Martine Remy-Jardin
Department of Medical Imaging, Radboud University Medical Center , Nijmegen
5 shared publications- David A. Lynch
Department of Radiology, National Jewish Health, Denver, Colo
4 shared publications - Fernando J. Martinez
University of Massachusetts Chan Medical School/UMass Memorial Health System, Worcester, Massachusetts, USA
4 shared publications - Kevin Wilson
Department of Medicine, Boston University School of Medicine, Boston, Massachusetts
4 shared publications - Kristine E. Konopka
Department of Pathology, University of Michigan, Ann Arbor, MI
4 shared publications
Latest Publications
- Open Access
- 21 July 2025
- Published by Wiley in Histopathology
- Vol. 88 (2) , 533-537
Immunohistochemical characterization of peritoneal inclusion cysts with squamous metaplasia
Aims: Peritoneal inclusion cysts (PICs) are mesothelial‐lined cysts that can uncommonly develop squamous metaplasia. Here, we describe the immunophenotype of PICs with squamous metaplasia using a comprehensive immunohistochemical (IHC) panel. Methods and results: We collected surgical excisions of PICs with squamous metaplasia from our institution and cases sent to our extramural consultation service. An IHC panel was used to characterize the immunophenotype, which included antibodies to claudin 4, WT‐1, D2‐40, calretinin, CK5/6, p40/p63, PAX8, BAP1, MTAP and merlin. 10 cases of PICs with squamous metaplasia were identified. The average age was 51 years, with 8 females and 2 males. On histology, all PICs ( n = 10) showed diffuse squamous metaplasia. The cyst lining cells exhibited a squamous epithelial phenotype with diffuse expression of claudin 4 and p63/p40 in the suprabasal cells that also showed consistent co‐expression of WT1 in all cases. In contrast, the basal layer displayed a mesothelial phenotype, demonstrating immunoreactivity to WT1 and D2‐40 and lacking expression of claudin 4. Calretinin showed complete loss of expression in both the basal and parabasal cells. All cases showed retained expression of BAP1, MTAP and merlin. Conclusions: PICs with squamous metaplasia express a unique mixed epithelial and mesothelial immunophenotype. The basal layer shows an immunophenotype consistent with mesothelial cells, and the suprabasal layers show an immunophenotype consistent with epithelial/squamous cells. Knowing the detailed immunophenotype of PIC with squamous metaplasia is helpful for correctly recognizing this lesion.
- 21 July 2025
- Published by Wiley in Histopathology
- Vol. 88 (2) , 533-537
Open AccessImmunohistochemical characterization of peritoneal inclusion cysts with squamous metaplasia
Aims: Peritoneal inclusion cysts (PICs) are mesothelial‐lined cysts that can uncommonly develop squamous metaplasia. Here, we describe the immunophenotype of PICs with squamous metaplasia using a comprehensive immunohistochemical (IHC) panel. Methods and results: We collected surgical excisions of PICs with squamous metaplasia from our institution and cases sent to our extramural consultation service. An IHC panel was used to characterize the immunophenotype, which included antibodies to claudin 4, WT‐1, D2‐40, calretinin, CK5/6, p40/p63, PAX8, BAP1, MTAP and merlin. 10 cases of PICs with squamous metaplasia were identified. The average age was 51 years, with 8 females and 2 males. On histology, all PICs ( n = 10) showed diffuse squamous metaplasia. The cyst lining cells exhibited a squamous epithelial phenotype with diffuse expression of claudin 4 and p63/p40 in the suprabasal cells that also showed consistent co‐expression of WT1 in all cases. In contrast, the basal layer displayed a mesothelial phenotype, demonstrating immunoreactivity to WT1 and D2‐40 and lacking expression of claudin 4. Calretinin showed complete loss of expression in both the basal and parabasal cells. All cases showed retained expression of BAP1, MTAP and merlin. Conclusions: PICs with squamous metaplasia express a unique mixed epithelial and mesothelial immunophenotype. The basal layer shows an immunophenotype consistent with mesothelial cells, and the suprabasal layers show an immunophenotype consistent with epithelial/squamous cells. Knowing the detailed immunophenotype of PIC with squamous metaplasia is helpful for correctly recognizing this lesion.
- 25 June 2025
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 56 (6) , 614-621
Analyzing the impact of the FISH! Philosophy on postpandemic workplace culture in an academic medical laboratory setting
Introduction: The post–COVID-19 work environment has seen widespread employee disengagement and increased turnover rates. To combat this negative cultural shift, the pathology department at a large academic medical center launched a culture-change initiative using the FISH! Philosophy program in fall 2023. Methods: Employees were invited to participate in FISH! Philosophy training and completed a baseline survey before attending (n = 125), a pulse survey at the conclusion of their session (n = 86), and a follow-up survey after 3 to 6 months (n = 53). Results: Employees responded positively to the training (94.1%). Improvement in job satisfaction (4.2% increase) and improved culture (reported by 49%) were noted, along with improvements in other key categories related to interpersonal relationships. Trust, however, saw a statistically significant decline (4.4%). Free-text comments were included in 42% of follow-up surveys, indicating that FISH! practices continue to be implemented in their work areas. Discussion: Although early results are mixed, positive movement has been observed in employee attitudes and behaviors. As more employees, and especially faculty and leadership, are trained, we anticipate that less resistance will be encountered, and lasting culture change will occur.
- 25 June 2025
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 56 (6) , 614-621
Analyzing the impact of the FISH! Philosophy on postpandemic workplace culture in an academic medical laboratory setting
Introduction: The post–COVID-19 work environment has seen widespread employee disengagement and increased turnover rates. To combat this negative cultural shift, the pathology department at a large academic medical center launched a culture-change initiative using the FISH! Philosophy program in fall 2023. Methods: Employees were invited to participate in FISH! Philosophy training and completed a baseline survey before attending (n = 125), a pulse survey at the conclusion of their session (n = 86), and a follow-up survey after 3 to 6 months (n = 53). Results: Employees responded positively to the training (94.1%). Improvement in job satisfaction (4.2% increase) and improved culture (reported by 49%) were noted, along with improvements in other key categories related to interpersonal relationships. Trust, however, saw a statistically significant decline (4.4%). Free-text comments were included in 42% of follow-up surveys, indicating that FISH! practices continue to be implemented in their work areas. Discussion: Although early results are mixed, positive movement has been observed in employee attitudes and behaviors. As more employees, and especially faculty and leadership, are trained, we anticipate that less resistance will be encountered, and lasting culture change will occur.
- 10 November 2022
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 60 (5) , 2201648
Transbronchial cryobiopsy: the right procedure for the right patient in the right place at the right time
This editorial assesses the impact of newly published ERS guidelines for use of transbronchial cryobiopsy for diagnosis of interstitial lung disease, including future areas of research likely to facilitate ongoing global adoptionhttps://bit.ly/3LAy1n8
- 10 November 2022
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 60 (5) , 2201648
Transbronchial cryobiopsy: the right procedure for the right patient in the right place at the right time
This editorial assesses the impact of newly published ERS guidelines for use of transbronchial cryobiopsy for diagnosis of interstitial lung disease, including future areas of research likely to facilitate ongoing global adoptionhttps://bit.ly/3LAy1n8
- Top Cited PapersOpen Access
- 15 August 2022
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 206 (4) , e7-e41
Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement
Background: The presence of emphysema is relatively common in patients with fibrotic interstitial lung disease. This has been designated combined pulmonary fibrosis and emphysema (CPFE). The lack of consensus over definitions and diagnostic criteria has limited CPFE research. Goals: The objectives of this task force were to review the terminology, definition, characteristics, pathophysiology, and research priorities of CPFE and to explore whether CPFE is a syndrome. Methods: This research statement was developed by a committee including 19 pulmonologists, 5 radiologists, 3 pathologists, 2 methodologists, and 2 patient representatives. The final document was supported by a focused systematic review that identified and summarized all recent publications related to CPFE. Results: This task force identified that patients with CPFE are predominantly male, with a history of smoking, severe dyspnea, relatively preserved airflow rates and lung volumes on spirometry, severely impaired DlCO, exertional hypoxemia, frequent pulmonary hypertension, and a dismal prognosis. The committee proposes to identify CPFE as a syndrome, given the clustering of pulmonary fibrosis and emphysema, shared pathogenetic pathways, unique considerations related to disease progression, increased risk of complications (pulmonary hypertension, lung cancer, and/or mortality), and implications for clinical trial design. There are varying features of interstitial lung disease and emphysema in CPFE. The committee offers a research definition and classification criteria and proposes that studies on CPFE include a comprehensive description of radiologic and, when available, pathological patterns, including some recently described patterns such as smoking-related interstitial fibrosis. Conclusions: This statement delineates the syndrome of CPFE and highlights research priorities.
- 15 August 2022
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 206 (4) , e7-e41
Top Cited PapersOpen AccessSyndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement
Background: The presence of emphysema is relatively common in patients with fibrotic interstitial lung disease. This has been designated combined pulmonary fibrosis and emphysema (CPFE). The lack of consensus over definitions and diagnostic criteria has limited CPFE research. Goals: The objectives of this task force were to review the terminology, definition, characteristics, pathophysiology, and research priorities of CPFE and to explore whether CPFE is a syndrome. Methods: This research statement was developed by a committee including 19 pulmonologists, 5 radiologists, 3 pathologists, 2 methodologists, and 2 patient representatives. The final document was supported by a focused systematic review that identified and summarized all recent publications related to CPFE. Results: This task force identified that patients with CPFE are predominantly male, with a history of smoking, severe dyspnea, relatively preserved airflow rates and lung volumes on spirometry, severely impaired DlCO, exertional hypoxemia, frequent pulmonary hypertension, and a dismal prognosis. The committee proposes to identify CPFE as a syndrome, given the clustering of pulmonary fibrosis and emphysema, shared pathogenetic pathways, unique considerations related to disease progression, increased risk of complications (pulmonary hypertension, lung cancer, and/or mortality), and implications for clinical trial design. There are varying features of interstitial lung disease and emphysema in CPFE. The committee offers a research definition and classification criteria and proposes that studies on CPFE include a comprehensive description of radiologic and, when available, pathological patterns, including some recently described patterns such as smoking-related interstitial fibrosis. Conclusions: This statement delineates the syndrome of CPFE and highlights research priorities.
- Top Cited PapersOpen Access
- 1 May 2022
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 205 (9) , e18-e47
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Background: This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of pulmonary fibrosis in patients with interstitial lung diseases (ILDs) other than IPF. Methods: A committee was composed of multidisciplinary experts in ILD, methodologists, and patient representatives. 1) Update of IPF: Radiological and histopathological criteria for IPF were updated by consensus. Questions about transbronchial lung cryobiopsy, genomic classifier testing, antacid medication, and antireflux surgery were informed by systematic reviews and answered with evidence-based recommendations using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. 2) Progressive pulmonary fibrosis (PPF): PPF was defined, and then radiological and physiological criteria for PPF were determined by consensus. Questions about pirfenidone and nintedanib were informed by systematic reviews and answered with evidence-based recommendations using the GRADE approach. Results: 1) Update of IPF: A conditional recommendation was made to regard transbronchial lung cryobiopsy as an acceptable alternative to surgical lung biopsy in centers with appropriate expertise. No recommendation was made for or against genomic classifier testing. Conditional recommendations were made against antacid medication and antireflux surgery for the treatment of IPF. 2) PPF: PPF was defined as at least two of three criteria (worsening symptoms, radiological progression, and physiological progression) occurring within the past year with no alternative explanation in a patient with an ILD other than IPF. A conditional recommendation was made for nintedanib, and additional research into pirfenidone was recommended. Conclusions: The conditional recommendations in this guideline are intended to provide the basis for rational, informed decisions by clinicians.
- 1 May 2022
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 205 (9) , e18-e47
Top Cited PapersOpen AccessIdiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Background: This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of pulmonary fibrosis in patients with interstitial lung diseases (ILDs) other than IPF. Methods: A committee was composed of multidisciplinary experts in ILD, methodologists, and patient representatives. 1) Update of IPF: Radiological and histopathological criteria for IPF were updated by consensus. Questions about transbronchial lung cryobiopsy, genomic classifier testing, antacid medication, and antireflux surgery were informed by systematic reviews and answered with evidence-based recommendations using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. 2) Progressive pulmonary fibrosis (PPF): PPF was defined, and then radiological and physiological criteria for PPF were determined by consensus. Questions about pirfenidone and nintedanib were informed by systematic reviews and answered with evidence-based recommendations using the GRADE approach. Results: 1) Update of IPF: A conditional recommendation was made to regard transbronchial lung cryobiopsy as an acceptable alternative to surgical lung biopsy in centers with appropriate expertise. No recommendation was made for or against genomic classifier testing. Conditional recommendations were made against antacid medication and antireflux surgery for the treatment of IPF. 2) PPF: PPF was defined as at least two of three criteria (worsening symptoms, radiological progression, and physiological progression) occurring within the past year with no alternative explanation in a patient with an ILD other than IPF. A conditional recommendation was made for nintedanib, and additional research into pirfenidone was recommended. Conclusions: The conditional recommendations in this guideline are intended to provide the basis for rational, informed decisions by clinicians.
- Open Access
- 8 April 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (4) , 937
The Octopus Sign—A New HRCT Sign in Pulmonary Langerhans Cell Histiocytosis
Background: Fibrosis in pulmonary Langerhans cell histiocytosis (PLCH) histologically comprises a central scar with septal strands and associated airspace enlargement that produce an octopus-like appearance. The purpose of this study was to identify the octopus sign on high-resolution computed tomography (HRCT) images to determine its frequency and distribution across stages of the disease. Methods: Fifty-seven patients with confirmed PLCH were included. Two experienced chest radiologists assessed disease stages as early, intermediate, or late, as well as the lung parenchyma for nodular, cystic, or fibrotic changes and for the presence of the octopus sign. Statistical analysis included Cohen’s kappa for interrater agreement and Fisher’s exact test for the frequency of the octopus sign. Results: Interobserver agreement was substantial for the octopus sign (kappa = 0.747). Significant differences in distribution of the octopus sign between stages 2 and 3 were found with more frequent octopus signs in stage 2 and fewer in stage 3. In addition, we only found the octopus sign in cases of nodular und cystic lung disease. Conclusions: The octopus sign in PLCH can be identified not only on histological images, but also on HRCT images. Its radiological presence seems to depend on the stage of PLCH.
- 8 April 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (4) , 937
Open AccessThe Octopus Sign—A New HRCT Sign in Pulmonary Langerhans Cell Histiocytosis
Background: Fibrosis in pulmonary Langerhans cell histiocytosis (PLCH) histologically comprises a central scar with septal strands and associated airspace enlargement that produce an octopus-like appearance. The purpose of this study was to identify the octopus sign on high-resolution computed tomography (HRCT) images to determine its frequency and distribution across stages of the disease. Methods: Fifty-seven patients with confirmed PLCH were included. Two experienced chest radiologists assessed disease stages as early, intermediate, or late, as well as the lung parenchyma for nodular, cystic, or fibrotic changes and for the presence of the octopus sign. Statistical analysis included Cohen’s kappa for interrater agreement and Fisher’s exact test for the frequency of the octopus sign. Results: Interobserver agreement was substantial for the octopus sign (kappa = 0.747). Significant differences in distribution of the octopus sign between stages 2 and 3 were found with more frequent octopus signs in stage 2 and fewer in stage 3. In addition, we only found the octopus sign in cases of nodular und cystic lung disease. Conclusions: The octopus sign in PLCH can be identified not only on histological images, but also on HRCT images. Its radiological presence seems to depend on the stage of PLCH.
- Open Access
- 23 November 2021
- Published by Elsevier in eClinicalMedicine
- Vol. 42, 101209
Usual Interstitial Pneumonia is the Most Common Finding in Surgical Lung Biopsies from Patients with Persistent Interstitial Lung Disease Following Infection with SARS-CoV-2
- 23 November 2021
- Published by Elsevier in eClinicalMedicine
- Vol. 42, 101209
Open AccessUsual Interstitial Pneumonia is the Most Common Finding in Surgical Lung Biopsies from Patients with Persistent Interstitial Lung Disease Following Infection with SARS-CoV-2
- Open Access
- 21 October 2021
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 145 (11) , 1326-1327
In Reply
- 21 October 2021
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 145 (11) , 1326-1327
Open AccessIn Reply